The assessment of a hematopoietic stem cell transplant (HSCT)-specific comorbidity index (HCT-CI) has been developed to predict the risk of TRM in patients undergoing allogeneic HSCT. As the myeloablative fludarabine/i.v. busulfan (FluBu4) regimen has been associated with limited extra-hematologic toxicity, we analyzed whether the HCT-CI represents a useful tool in transplant patients conditioned with this regimen. Of the 52 consecutive patients who received an allogeneic HSCT with FluBu4 at our institution, 50 were evaluable for assessing pre-transplant HCT-CI. Patients were divided into three groups: score 0 (n ¼ 7); score 1-2 (n ¼ 17) and score 43 (n ¼ 26). The three groups did not differ significantly in age, diagnosis, previous lines of chemotherapy and type of donor. High-risk disease was present in 57% of low, 82% of intermediate and 85% of high HCT-CI score groups (P ¼ ns). Two-year TRM and OS was 14.3 and 85.7% in the low score group, 23.5 and 58.8% in the intermediate score group and 15.4 and 50% in the high HCT-CI score group (P ¼ ns). In this study, the HCT-CI lacked sensitivity to reliably predict TRM although patients with no comorbidities showed a trend for improved survival.
Introduction
Allogeneic transplant hematopoietic stem cell transplant (HSCT) is the best curative option for many hematologic disorders. However, it is still associated with a variable risk of transplant-related complications. The main causes of non-relapse morbidity encompass GVHD, infection and cytopenias. 1 The use of conditioning regimens at reduced intensity has significantly increased the age limit for HSCT. Nevertheless, elderly patients often present with more comorbidities causing increased post-HSCT morbidity and mortality. Therefore, the development of a method to reliably assess pre-transplant comorbidities is important for clinicians to estimate the risks of undergoing HSCT. In addition, it should help to better standardize patient populations for comparison across clinical trials in HSCT.
Initial studies analyzed which comorbidities have the greatest effect on outcome in those patients undergoing HSCT 2, 3 and developed the hematopoietic cell transplantspecific comorbidity index (HCT-CI), which is a weighted score designed to predict TRM. The HCT-CI was developed in a heterogenous population with 470% of patients conditioned with standard myeloablative and the remaining with a non-myeloablative conditioning regimen. 3 Among new conditioning regimens for allogeneic HSCT, fludarabine/i.v. busulfan conditioning has recently gained popularity based on its limited extra-hematoloic toxicity, while including myeloablative doses of busulfan. 4 Here, we addressed the question of whether the HCT-CI can also be a useful tool to predict TRM in myeloablative allogeneic HSCT conditioned with fludarabine/i.v. busulfan. The analysis of 52 consecutive patients transplanted at our institution is reported.
Materials and methods

Patients
In this study, we retrospectively analyzed 52 consecutive adult patients with hematologic malignancies who underwent allogeneic peripheral blood (n ¼ 45) or BM (n ¼ 7) HSCT. Patients received conditioning with fludarabine/i.v. busulfan after signing an informed consent according to a protocol approved by the University of Illinois at Chicago Institutional Review Board.
Diagnoses were based upon WHO classification. Patients with acute leukemia were considered at high risk of relapse if they were in greater than first CR, failed to achieve remission after first induction chemotherapy, were in relapse or if they possessed established molecular or cytogenetic markers of high risk. Patients with nonHodgkin's lymphoma, myelodysplastic syndrome other than refractory anemia and CML in accelerated phase were also considered at high risk. All other patients were considered to have standard risk diagnoses.
Comorbidity scoring system A pre-transplant HCT-CI score was calculated retrospectively for each patient. Scores and definition of comorbidities 3 are shown in Table 1 along with the prevalence of each comorbidity in our population. Of the 52 patients, 50 patients had complete clinical data allowing assessment of HCT-CI and 2 patients did not have complete information and were therefore excluded from the analysis. Patients were divided into three groups: low score (score ¼ 0); intermediate score (score 1-2) and high score (score 43) as previously reported. 3 
Donors
Of the 50 patients, 28 received a transplant from a related donor and 22 from an unrelated donor. HLA typing in related donors was performed by low resolution molecular typing for class I (A, B and C) and class II (HLA-DRB1) loci. High-resolution molecular testing was performed for class I and class II loci in unrelated transplants. Forty-seven patients received HLA-matched grafts. Three patients with unrelated donors received HLA-mismatched grafts (one patient with two allele mismatch and two patients with single-antigen mismatch).
Transplantation
All patients were conditioned with fludarabine at a dose of 40 mg/m 2 per day i.v. on days -9 through -6 and i.v. busulfan on days -5 through -2 (FluBu4). I.v. busulfan was administered at a total dose of 12.8 mg/kg, or to target an AUC of 4800 mmol/min, as previously described. and tacrolimus (from day -2). Tacrolimus level was maintained at 5-15 ng/ml until day 180 unless the patient experienced GVHD or disease recurrence. Twenty-two patients with unrelated donors and one patient with CML also received rabbit anti-thymocyte globulin (ATG, Genzyme Inc., Cambridge, MA, USA) from day -3 to day -1 as previously described. 6 All patients received infection prophylaxis with fluconazole and acyclovir from day -2 until day 180. Patients also received pneumocystis jiroveci prophylaxis with trimethoprim-sulfamethoxazole or inhaled pentamidine from engraftment until day 180 or longer on immunosuppressive treatment for GVHD.
Statistical methods
Categorical variables were compared using w 2 test. Continuous variables were compared using analysis of variance. TRM was measured from time of transplant to death from any cause other than disease relapse. Survival curves were drawn using Kaplan-Meier method and differences between curves were assessed by the log-rank test. Hazard ratios and 95% confidence interval for TRM and OS were estimated using Cox proportional hazard regression analysis.
Results
Comorbidity index and diagnosis
Of the 50 patients, 7 (14%) had score 0, 17 (34%) had score 1-2 and 26 (52%) had score 43. Pulmonary comorbidities were the most common with greater than half of the patients having either moderate (32%) or severe (22%) pulmonary disease according to the HCT-CI. Infection and mild hepatic comorbidities were found in 28 and 32% of patients, respectively. No patients had arrhythmias, peptic ulcer disease, renal disease or severe liver disease under the established definitions.
The three groups did not differ significantly in age, diagnosis, previous lines of chemotherapy or type of donor ( Table 2 ). As shown in Table 2 , a high proportion of patients in each group had a high-risk disease: 57% in the low score, 82% in the intermediate score and 85% in the high score group (P ¼ ns). The majority of transplants were performed for acute leukemia (n ¼ 30). Patients with active acute leukemia at the time of HSCT were 12% in low score group, 18% in the intermediate and 29% in the high score group (P ¼ ns). Differences were not statistically significant for any characteristic analyzed in the three groups. There was a trend toward fewer patients with AML in 4CR1 or in relapse (P ¼ 0.06) in the low score group compared with the intermediate and high score groups.
Comorbidity index and outcome Overall, 13 patients (26%) died due to relapse of their malignancy and 11 (22%) due to transplant-related complications (Table 3) . Median follow-up in the low risk, intermediate risk and high risk was 770, 476 and 713 days, respectively. Hazard ratio and 2-year incidence of TRM and OS are summarized by HCT-CI scores in Table 4 . Two-year TRM was low across all groups: 14.3% in the low; 23.5% in the intermediate and 15% in the high comorbidity score group (P ¼ ns). This is despite the fact that the rate of acute GVHD grades II-IV was slightly lower in the low score group (14%) compared with the intermediate (30%) and high score (34%) groups (P ¼ ns). Rates of extensive chronic GVHD were 29% in the low, 30% in the intermediate and 43% in the high score group. There were no cases of death due to disease relapse in the low score group in contrast to the intermediate (18%) and the high score group (39%).
Hazard ratio for OS was 5.04 (95% confidence interval: 0.64-39.9) in the intermediate score group and 5.38 (95% confidence interval: 0.71-41.1) in the high score group (Table 4) . Two-year OS was 85.7, 58.8 and 50% in the low, intermediate and high score group. Although OS in the three groups was not statistically different (Figure 1 ), there was a trend toward improved survival in the low score group. This was further demonstrated by comparing OS in intermediate-and high-risk score groups pooled together vs low-risk patients (P ¼ 0.1) (not shown). The hazard ratio and the corresponding 95% confidence interval are 5.24 (0.71-38.91).
Discussion
In this study, we showed that in a population of patients who had undergone allogeneic HSCT after receiving myeloablative conditioning with fludarabine/i.v. busulfan, the HCT-CI may not reliably stratify patients with different risk of death.
HCT-CI has now been studied in several different diseases, conditioning regimens and donor types with varying results. Sorror et al.
3 first described the HCT-CI and showed that in a single-center TRM and OS could be predicted by dividing patients into three groups based on HCT-CI score. The same center subsequently showed that high HCT-CI predicted outcomes (TRM and OS) in patients with AML, myelodysplastic syndrome, CLL and lymphoma conditioned with both myeloablative and nonmyeloablative regimens. 7, 8 Similar results were obtained when the Seattle data on AML patients in first CR was combined with data from the MD Anderson cancer center. 9 In data presented here, we find no statistically significant difference between HCT-CI (as stratified into 0, 1-2 and 43) in terms of OS or TRM. However, we do note that there is a trend toward improved OS in those patients without any comorbidities, in comparison to all other patients. We acknowledge that among possible reasons for lack of statistical significance, there can be the small number of patients with no comorbidities. It should be noted that relapse contributed to mortality in the intermediate and high score groups to a much greater degree 
Abbreviations: ATG ¼ anti-thymocyte globulin; MDS ¼ myelodysplastic syndrome. a High risk indicated by leukemia with high-risk molecular markers or cytogenetics, in 4CR1, or failed initial induction therapy, MDS other than refractory anemia, CML other than in first chronic phase, NHL. than in the low comorbidity group. This finding may be related to the increased number of patients with high-risk disease and leukemia in relapse or 4CR1 in the intermediate and high score groups. Data regarding the utility of the HCT-CI has been mixed. A Canadian group reported that they found no association between HCT-CI and TRM or OS in a variety of conditioning regimens and disease. 10 In umbilical cord transplant registry data, HCT-CI did not consistently predict TRM or OS. 11 Similarly, in patients with nonHodgkin's lymphoma conditioned with fludarabine and CY, there was no association between HCT-CI and TRM or OS. 12 Several investigators have reported that although HCT-CI may be useful, it lacks the sensitivity to predict outcome as stratified by the three original groups described. Farina et al. 13 reported that in patients with myeloma or lymphoma who underwent reduced intensity or nonmyeloablative conditioning, HCT-CI of 0 was associated with a significantly improved OS and TRM when compared with both of the other groups. TRM was not different between patients with HCT-CI of 1-2 and HCT-CI of X3 (P ¼ 0.48). Therefore, in this population the HCT-CI lacked sensitivity to predict outcomes in patients with HCT-CI score 41. Conversely, in patients conditioned with fludarabine/oral busulfan and i.v. alemtuzumab although TRM seems to show linear increase with increasing HCT-CI score (16 vs 24 vs 42%), the difference was not statistically different between patients with 0 score and 1-2 but was significantly increased in patients with HCT-CI X3.
14 Similarly, a single-center Japanese experience showed that patients with high HCT-CI score had statistically worse OS and TRM than low score patients. The same was not true for patients with intermediate score HCT-CI. 15 Attempts have been made to increase the sensitivity of the HCT-CI. The original investigators have reported that the addition of Karnofsky performance score or disease risk at the time of transplant enhances the stratification and gives incremental increases in non-relapse mortality. 16 Interestingly, Barba et al. 17 reported that in patients conditioned with fludarabine/melphalan or fludarabine/ busulfan (8-10 mg/kg), there was no association between HCT-CI and TRM or OS. However, when the same investigators analyzed patients compartmentalized in a different manner, they found this new flexible HCT-CI was a strong predictor of TRM and OS.
One possible explanation for the lack of correlation of HCT-CI with outcome is that there could be different rates of toxicity associated with the conditioning regimen. Our study contained few patients with no comorbidities. As compared with previous findings on standard myeloablative transplants, 3 we hypothesize that the low toxic effect of FluBu4 is likely to reduce the risk of TRM in patient with intermediate-or high-risk HCT-CI. However, in contrast to this hypothesis, the HCT-CI was found to be useful in patient receiving a non-myeloablative regimen. 7, 8 Recently, it has been suggested that more studies to validate the HCT-CI are required in homogenous patient populations. 18 To our knowledge, this is the first study to evaluate the validity of HCT-CI in patients conditioned with fludarabine/i.v. busulfan at myeloablative doses. Although here the HCT-CI could not stratify patients with different outcome, this score may still be a useful tool to identify patients at very low risk and likely better outcome. 
